Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)
Symptoms, Doctors, Treatments, Advances & More

Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Overview

Save information for later
Sign Up

Learn About Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Local Doctors?
Elite in Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)
Neuromusculoskeletal Medicine
Elite in Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)
Neuromusculoskeletal Medicine

Emory Brain Health Center

12 Executive Park Drive Northeast, 
Atlanta, GA 
Experience:
41+ years
Languages Spoken:
English
Offers Telehealth

Jonathan Glass is a Neuromusculoskeletal Medicine provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 41 years. Dr. Glass is rated as an Elite provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Spinal and Bulbar Muscular Atrophy, and Gastrostomy. Dr. Glass is board certified in American Board Of Pathology, 1997.

Elite in Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)
Neuromusculoskeletal Medicine
Elite in Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)
Neuromusculoskeletal Medicine

Johns Hopkins Outpatient Center

601 North Caroline Street, Floor 5, Floor 5, 
Baltimore, MD 
Languages Spoken:
English

Nicholas Maragakis treats patients with motor neuron diseases, such as amyotrophic lateral sclerosis (ALS). This care is coordinated with the Johns Hopkins Center for ALS Specialty Care, a multidisciplinary clinic with expertise in treating patients with ALS and providing support to their caregivers. He serves as medical director of the ALS Clinical Trials Unit, an extension of the multidisciplinary clinic that seeks to facilitate opportunities for patients with ALS to participate in clinical trials that could advance the treatment of this disease. Dr. Maragakis is interested in the basic science of understanding neurodegenerative diseases, as well as the translational potential of therapeutic compounds developed in the laboratory. His fundamental research interest is in using stem cells — more specifically, stem cell-derived motor neurons and glia — for understanding the development and propagation of ALS. His laboratory has been involved in creating and characterizing lines of stem cells from patients with ALS using induced pluripotent stem cell (iPSC) methodologies. The laboratory has a large library of iPSCs from patients with familial ALS and from patients with sporadic ALS. The utilization of this library of iPSCs has facilitated the development of a spinal cord-specific iPSC-astrocyte/motor neuron co-culture system, which has been leveraged for the development of assays that can be used for both the basic understanding of ALS astrocyte and motor neuron biology as well as, eventually, drug screening for ALS therapeutics. His laboratory has taken its long-standing interests in astrocyte biology, as it relates to ALS, to develop a program that investigates astrocyte-specific mechanisms as contributors to the progression (both temporally and anatomically) of disease in ALS. In this vein, there is an interest in astrocytic glutamate transporters and, more recently, astrocyte hemichannels and gap junctions. Dr. Maragakis is rated as an Elite provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, 15q11.2 Microdeletion, and Spinal Muscular Atrophy (SMA).

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)
Neurology | Neuromusculoskeletal Medicine
Elite in Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)
Neurology | Neuromusculoskeletal Medicine

Atrium Health Neurology Specialty Care, A Facility Of Carolinas Medical Center

1010 Edgehill Road N., 
Charlotte, NC 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Leo Mccluskey is a Neurologist and a Neuromusculoskeletal Medicine provider practicing medicine in Charlotte, North Carolina. Dr. Mccluskey is rated as an Elite provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), and Spinal and Bulbar Muscular Atrophy. Dr. Mccluskey is board certified in American Board Of Psychiatry And Neurology, Neuromuscular Medicine and American Board Of Electrodiagnostic Medicine. Dr. Mccluskey is currently accepting new patients.

What are the latest Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials?
HEALEY ALS Platform Trial

Summary: The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study With Additional 24-Week Blinded Active Extension to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Summary: The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS). COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of r...